Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

InsightsRegulatory Updates

Regulatory update

AWMF S3 Guidelines: What the Rules Require from Systematic, Rapid and Scoping Reviews

The S-classes, Regelwerk 2.2, IQWiG evidence reports, GRADE and German recommendation wording, consensus thresholds, conflict-of-interest rules and a delivery checklist for review teams, current as of November 2026.

Dr. CharlieSenior Medical WriterPublishedReading time11 minutesSources18
  • Germany
  • Guidelines
  • Systematic review
  • Regulatory update

At a glanceRegulatory Updates

Rulebook
AWMF Regelwerk 2.2 (May 2025)
S3 means
Systematic evidence review plus structured consensus
IQWiG role
Evidence reports for guideline groups since 2020
Validity
Maximum 5 years; living guidelines updated at least every 12 months

Explore systematic review servicesDiscuss your project

Quick answer

  • AWMF guidelines are recommendations developed by Germany’s scientific medical societies under the AWMF Regelwerk (version 2.2, 2025), not statutory regulation1.
  • S3 is the only class that combines a systematic evidence review with structured consensus by a representative panel, so every key question needs a documented search, selection, appraisal and evidence summary1.
  • Since 2020, IQWiG can prepare evidence reports for guideline groups under § 139a(3) no. 3 and § 139b(6) SGB V; the guideline group still formulates and votes on the recommendations2.
  • Rapid reviews can feed S3 work if every shortcut is stated3; scoping reviews help refine key questions but rarely support graded recommendations on their own.

Overview: what is current in November 2026

The AWMF (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, the Association of the Scientific Medical Societies in Germany) is the umbrella body for 185 scientific medical societies, according to its 2025 annual report4. Through its rulebook, the AWMF Regelwerk, it sets the methodological standards a guideline must meet to be classified and published in the AWMF guideline register15.

AWMF guidelines are professional-society recommendations, not regulation. They are not laws and are not issued by a government agency. They carry weight because they describe the scientifically supported standard of care, and because statutory bodies sometimes draw on them.

This article explains what the Regelwerk asks of the evidence behind an S3 guideline, how systematic, rapid and scoping reviews fit in, and where IQWiG evidence reports and Innovationsfonds funding come in.

Status as of 22 November 2026

  • AWMF Regelwerk version 2.2 (summary of changes dated 22 May 2025) is the current rulebook. According to AWMF’s summary, the main changes were notes on the new digital registration procedure, a clarified consensus-strength table, clarified requirements for neutral moderation, and new help documents (for example on statutory funding options and digital tools for consensus)1.
  • IQWiG General Methods version 8.0 took effect on 19 December 2025; the English translation followed on 1 July 20266.
  • IQWiG’s generic project outline for evidence reports on intervention questions is at version 2.0 (30 June 2025)7.
  • Only the documents published at awmf.org/regelwerk are valid. Check them, and the methods report of your own guideline, before you rely on a specific rule.

The AWMF S-classification

The Regelwerk classifies guidelines by two things: how systematically the evidence was searched and appraised, and how formally consensus was reached1.

Table 1. AWMF guideline classes (summarised from the AWMF Regelwerk)

ClassBasisSystematic evidence reviewStructured consensus with a representative panelHow recommendations are graded
S1Recommendations of an expert groupNoNo (informal consensus)Not graded
S2kConsensus-basedNoYesWording only (soll / sollte / kann), with no evidence or recommendation grades
S2eEvidence-basedYes: systematic search, selection and appraisalNoLinked to the appraised evidence (evidence levels)
S3Evidence- and consensus-basedYesYesRecommendation grades, plus evidence certainty or levels

S2e versus S3. An S2e guideline must rest on a systematic evidence review and link each recommendation to the appraised evidence, but it is not agreed through a structured consensus process with a representative panel. S3 adds that consensus step. In practice the evidence work for S2e and S3 is similar, so review teams should plan for the same documentation either way.

Two large programmes produce many S3 guidelines and publish detailed methods reports that are useful models: the Leitlinienprogramm Onkologie (German Guideline Program in Oncology)8 and the Nationale VersorgungsLeitlinien (NVL, National Disease Management Guidelines)9.

IQWiG evidence reports and Innovationsfonds funding

Since 2020, the Institute for Quality and Efficiency in Health Care (IQWiG) has had a statutory task under § 139a(3) no. 3 and § 139b(6) SGB V (German Social Code, Book V) to support guideline development with evidence research2. The process, as IQWiG describes it:

  1. The AWMF proposes guideline topics and questions to the Federal Ministry of Health (BMG).
  2. If the BMG accepts a proposal, it commissions IQWiG to prepare an evidence report (Evidenzbericht) on the agreed questions.
  3. IQWiG also invites societies to contact it directly, before or alongside registering the project with the AWMF, which remains the main point of contact2.

IQWiG’s generic project outline for intervention questions sets out the report structure: question formulation agreed at a kick-off with the guideline coordinators and the AWMF, systematic searches, study selection, data extraction, risk of bias assessment and a GRADE assessment of the certainty of evidence, presented in evidence profiles per outcome7. The General Methods describe how IQWiG produces these reports6. IQWiG does not write the recommendations: the guideline group still formulates, grades and votes on them.

Published S3 guidelines show how this works in practice. The S3 guideline on vaginal birth at term (AWMF registry no. 015/083), for example, reports that it used IQWiG evidence reports to assess the quality of evidence10.

Funding. Since 2020, the Innovationsfonds run by the Federal Joint Committee (G-BA) has also funded the development and updating of selected guidelines where there is a particular need in care11. Budgets and eligibility are set in each funding announcement, so check the current call rather than relying on past amounts.

For the wider German HTA picture, see our guides to the IQWiG General Methods on meta-analysis and the EU HTA Regulation and joint clinical assessments.

Evidence reviews for German guideline groups

Pubrica’s systematic review team supports guideline groups with PICO key questions, documented searches, screening, risk of bias assessment, GRADE evidence profiles and rapid reviews that list every shortcut, in a format ready for the Leitlinienreport. We work to the group’s methods plan and the current AWMF Regelwerk but are not affiliated with or accredited by the AWMF. The guideline group keeps ownership of and responsibility for the recommendations, and timelines are agreed project by project.

What S3 guidelines require from evidence reviews

At S3 level, each key question must be answered with systematically identified and appraised evidence, and the whole process must be documented in the guideline report (Leitlinienreport) published alongside the guideline1. Whether the evidence comes from your own team, a commissioned contractor or IQWiG, guideline groups typically expect:

  • Key questions agreed by the guideline group and structured with PICO (population, intervention, comparison, outcome) or an adapted framework for diagnostic, prognostic or qualitative questions.
  • Patient-relevant outcomes, prioritised with input from patient representatives in the guideline group.
  • A systematic search with documented strategies, sources and dates. Many groups start by searching for high-quality guidelines and systematic reviews, then update them with primary studies. Report the search in line with PRISMA-S.
  • Transparent selection against prespecified criteria, with reasons for exclusion and a flow diagram (see our PRISMA 2020 flowchart guide).
  • Risk of bias or methodological quality assessment with a recognised tool (see which risk of bias tool to use).
  • Evidence summaries: evidence tables and, increasingly, GRADE evidence profiles or summary-of-findings tables per outcome.

Adapting existing guidelines. A group does not always have to start from scratch. Where a recent, high-quality guideline exists, recommendations can be adopted or adapted using a documented method such as ADAPTE12 or GRADE-ADOLOPMENT, which combines adoption, adaptation and de novo development within GRADE Evidence to Decision frameworks13. AWMF has published a help document on adoption and adaptation of guideline recommendations (2023)1. The source guideline is then appraised and its evidence updated, and the methods must still be reported in the Leitlinienreport.

Systematic, rapid and scoping reviews compared

The Regelwerk asks for a systematic evidence base at S3 level, but it does not set out a separate rulebook for each review type. Table 2 is therefore practice guidance drawn from methods literature and guideline methods reports, not a list of AWMF rules. Agree the approach for each key question with the guideline group and its AWMF advisor, and record it in the Leitlinienreport.

Table 2. How review types typically support guideline development (practice guidance, not Regelwerk rules)

AspectSystematic reviewRapid reviewScoping review
Typical roleMain evidence base for graded recommendationsFaster evidence for urgent questions or updates, including living guidelinesMapping a topic, finding gaps and refining key questions
SearchComprehensive, several databases plus other sourcesStreamlined (for example fewer databases, date or language limits)Broad and mapping-oriented
ScreeningTwo reviewers, independentlyOne reviewer with a second reviewer checking a sample or the exclusionsUsually two reviewers, often iterative
AppraisalRisk of bias requiredRisk of bias required, sometimes simplifiedNot usually done
OutputEvidence tables, GRADE profilesEvidence summary with every shortcut statedEvidence map or descriptive charting

Rapid reviews. The Cochrane Rapid Reviews Methods Group’s updated guidance (2024) recommends involving the review’s end users when setting the question, prespecifying the streamlined methods in a protocol, and reporting every shortcut so that readers can judge the risk of missed evidence314. In a guideline report, list each shortcut next to the key question it affects.

Scoping reviews. A scoping review maps what evidence exists. It does not usually appraise study quality or estimate effects, so on its own it rarely supports a graded recommendation. It is most useful before the key questions are fixed. See how to write a scoping review, the PRISMA-ScR checklist explained and where to register a review protocol.

Grading evidence and recommendations

Many S3 guidelines use GRADE to rate the certainty of evidence for each outcome as high, moderate, low or very low. Certainty can be downgraded for risk of bias, inconsistency, indirectness, imprecision and publication bias, and upgraded in some cases, such as a large effect15. Other S3 guidelines use evidence levels such as the Oxford CEBM or SIGN schemes; the Leitlinienreport must state which system was used.

Recommendation strength is then expressed in standard German wording. The grades below are widely used in AWMF S3 guidelines, including negative forms for recommendations against an intervention1:

Table 3. Recommendation grades and standard wording commonly used in AWMF S3 guidelines

GradeGerman wording (for)English meaningGerman wording (against)English meaningIllustrative example (fictional)
A (strong recommendation)sollshallsoll nichtshall not“Adults with condition X shall (soll) be offered intervention Y.”
B (recommendation)sollteshouldsollte nichtshould not“Intervention Z should not (sollte nicht) be used routinely in condition X.”
0 (open recommendation)kannmaykann verzichtet werdenmay be omitted“Intervention W may (kann) be considered for condition X.”

The grade is not a mechanical translation of evidence certainty. The panel may grade up or down for reasons such as the balance of benefits and harms, patient preferences, applicability or resource use, and those reasons should be stated next to the recommendation. Many programmes also allow expert consensus (often labelled EK) recommendations where no adequate evidence was found; check how your guideline defines them.

Structured consensus and conflicts of interest

S3 recommendations are agreed through a structured consensus process, such as a nominal group technique, a structured consensus conference or a Delphi process, usually with neutral moderation. The panel must be representative of the intended users and should include patient representatives1. Consensus strength is reported for every recommendation, using the AWMF categories in Table 416.

Table 4. AWMF consensus strength categories

CategoryGerman termAgreement among voting participants
Strong consensusstarker Konsens>95%
ConsensusKonsens>75% to 95%
Majority agreementmehrheitliche Zustimmung>50% to 75%
No majority agreementkeine mehrheitliche Zustimmung≤50%

Conflicts of interest. Everyone involved must declare their interests. The declarations are assessed for relevance to the guideline topic and graded as low, moderate or high, with consequences that the Regelwerk sets out1:

Table 5. Conflict-of-interest categories and typical consequences under the AWMF Regelwerk

RelevanceTypical consequence
LowNo leading role, such as coordinator or chair of a working group, on the affected topic
ModerateAbstains from votes on recommendations related to the conflict (or a double vote with and without conflicted members, where the guideline’s methods allow it)
HighExcluded from discussion and voting on the related topics

Evidence review teams are affected too: declare your own interests, keep the evidence work separate from the voting, and make sure the Leitlinienreport says how conflicts were assessed and managed.

Validity, updating and living guidelines

An AWMF guideline is valid for at most five years. After that it must be updated; otherwise it is flagged in the register as no longer current and is eventually archived15.

Living guidelines update individual recommendations as soon as relevant new evidence appears, so the unit of update is the recommendation, not the whole guideline17. In the AWMF register, a living guideline is registered for a maximum of five years and its update interval must be no longer than 12 months18. That depends on repeatable surveillance searches and rapid, well-documented evidence updates, often run as a living systematic review.

Worked example: from key question to graded recommendation

Illustrative example. The scenario below is fictional and shows the chain of documentation a guideline group will expect for one key question.

Table 6. One key question traced through an S3 evidence workflow (illustrative)

StepWhat the review team deliversWhere it is reported
1. Key questionPICO: adults with condition X; intervention Y vs usual care; outcomes agreed with patient representatives (for example mortality, function, serious adverse events)Leitlinienreport
2. SearchSearch for guidelines and systematic reviews, then an update search for randomised trials in at least two databases plus a trial registry; strategies, dates and limits recordedLeitlinienreport appendix
3. SelectionTwo reviewers screen independently; exclusions with reasons; flow diagramLeitlinienreport
4. AppraisalRisk of bias per study with a stated toolEvidence tables
5. CertaintyGRADE profile per outcome (for example moderate certainty for function, low for adverse events)Evidence profile
6. Consensus votePanel drafts “Intervention Y sollte be offered…” (grade B); votes, with conflicted members abstaining; result: consensus (for example 88%)Guideline text and Leitlinienreport

If a rapid review had been used for step 2, the team would add a line listing each shortcut (for example a single database or English-only limits) and how it might affect the conclusion.

Checklist for evidence review teams

Use this before delivering evidence to an S3 guideline group. It summarises the points above and complements the guideline group’s own methods plan1315.

S3 evidence delivery checklist

  • Key questions are agreed with the guideline group and structured with PICO or an adapted framework.
  • Outcomes are prioritised with patient representatives.
  • The current Regelwerk version (2.2 as of November 2026) and the guideline’s methods plan have been checked.
  • Search strategies, sources, dates and limits are fully documented.
  • Inclusion criteria, screening process and reasons for exclusion are transparent.
  • Risk of bias and certainty of evidence are assessed per outcome, with the system named.
  • Any rapid-review shortcuts are listed against the key questions they affect.
  • If existing guidelines were adopted or adapted, the method (for example ADAPTE or GRADE-ADOLOPMENT) is stated.
  • Review team interests are declared.
  • Evidence tables and profiles are ready for the Leitlinienreport.

Conclusion

S3 is the most demanding AWMF class: a systematic evidence review, transparent appraisal, structured consensus and managed conflicts of interest, all documented in the Leitlinienreport. As of November 2026, the reference points are Regelwerk 2.2 and, where IQWiG is commissioned, its evidence report methods.

Review teams that document every step, state every rapid-review shortcut and keep scoping reviews for refining questions give guideline groups evidence that is easier to assess and trust. For worked scenarios, see our review type and protocol case studies and the scoping review, PRISMA-ScR and AWMF Q&A.

Pubrica team verdict

For an S3 guideline, the review method matters less than whether every step and every shortcut can be traced from the key question to the voted recommendation in the Leitlinienreport.

Frequently asked questions

The Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (Association of the Scientific Medical Societies in Germany). It is the umbrella body for 185 scientific medical societies (2025) and runs the German guideline register and the rules for guideline development, the AWMF Regelwerk.

No. They are recommendations developed by scientific medical societies under the AWMF’s own rules, not statutory regulation. They describe the scientifically supported standard of care, and clinicians can depart from them for good reason in an individual case.

As of November 2026, version 2.2, with a summary of changes dated 22 May 2025. Only the documents at awmf.org/regelwerk are valid, so check there before a project starts.

Both rest on a systematic search, selection and appraisal of the evidence. S3 also requires a structured consensus process with a representative panel; S2e does not.

Yes, if the approach is agreed with the guideline group, every shortcut is stated and justified, and the methods are documented in the Leitlinienreport. The 2024 Cochrane rapid review guidance is a useful reference.

Rarely on its own. Scoping reviews map the evidence and usually do not appraise study quality or estimate effects, so they are best used to refine key questions before the systematic or rapid reviews.

Since 2020, the Federal Ministry of Health can commission IQWiG, on AWMF proposals, to research the evidence for guideline questions under § 139a(3) no. 3 and § 139b(6) SGB V. The report covers search, selection, risk of bias and GRADE certainty; the guideline group still writes and votes on the recommendations.

Agreement of more than 95% of voting participants. Consensus is more than 75% to 95%, majority agreement more than 50% to 75%, and 50% or less is no majority agreement.

At most five years. Living guidelines are registered for up to five years and must be updated at intervals of no more than 12 months.

Sources

Sources were checked on 22 November 2026. Requirements and guidance may change after that date; confirm the current version with the issuing body.

  1. 1Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) – Ständige Kommission Leitlinien. AWMF-Regelwerk „Leitlinien“. Version 2.2 [Internet]. Berlin: AWMF; 2025 (summary of changes dated 2025 May 22) [cited 2026 Nov 22]. Available from: https://www.awmf.org/regelwerk
  2. 2Institute for Quality and Efficiency in Health Care (IQWiG). Evidence searches for medical guidelines [Internet]. Cologne: IQWiG; [cited 2026 Nov 22]. Available from: https://www.iqwig.de/en/presse/in-the-focus/evidence-searches
  3. 3Garritty C, Hamel C, Trivella M, Gartlehner G, Nussbaumer-Streit B, Devane D, et al. Updated recommendations for the Cochrane rapid review methods guidance for rapid reviews of effectiveness. BMJ. 2024;384:e076335. https://doi.org/10.1136/bmj-2023-076335
  4. 4Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Jahresbericht 2025 [Internet]. Berlin: AWMF; 2026 [cited 2026 Nov 22]. Available from: https://www.awmf.org/fileadmin/user_upload/dateien/publikationen/jahresberichte/AWMF-Jahresbericht_2025.pdf
  5. 5Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). AWMF guideline register [Internet]. [cited 2026 Nov 22]. Available from: https://register.awmf.org/
  6. 6Institute for Quality and Efficiency in Health Care (IQWiG). General Methods: Version 8.0 [Internet]. Cologne: IQWiG; 2025 Dec 19 (English version published 2026 Jul 1) [cited 2026 Nov 22]. Available from: https://www.iqwig.de/methoden/general-methods_version-8-0.pdf
  7. 7Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Generische Projektskizze für Evidenzberichte mit Fragestellungen zu Interventionen. Version 2.0 [Internet]. Köln: IQWiG; 2025 Jun 30 [cited 2026 Nov 22]. Available from: https://iqwig.de/printprodukte/generische-projektskizze-fuer-evidenzberichte-mit-fragestellungen-zu-interventionen_v2-0.pdf
  8. 8Leitlinienprogramm Onkologie (German Guideline Program in Oncology) of the AWMF, Deutsche Krebsgesellschaft and Deutsche Krebshilfe [Internet]. [cited 2026 Nov 22]. Available from: https://www.leitlinienprogramm-onkologie.de/
  9. 9Programm für Nationale VersorgungsLeitlinien (NVL) of the Bundesärztekammer, Kassenärztliche Bundesvereinigung and AWMF [Internet]. [cited 2026 Nov 22]. Available from: https://www.leitlinien.de/
  10. 10Abou-Dakn M, Schäfers R, Peterwerth N, Asmushen K, Bässler-Weber S, Boes U, et al. Vaginal birth at term - part 1. Guideline of the DGGG, OEGGG and SGGG (S3-level, AWMF registry no. 015/083, December 2020). Geburtshilfe Frauenheilkd. 2022;82(11):1143-93. https://doi.org/10.1055/a-1904-6546
  11. 11Bundesministerium für Gesundheit. Innovationsfonds [Internet]. Berlin: BMG; [cited 2026 Nov 22]. Available from: https://www.bundesgesundheitsministerium.de/service/begriffe-von-a-z/i/innovationsfonds.html
  12. 12Fervers B, Burgers JS, Voellinger R, Brouwers M, Browman GP, Graham ID, et al. Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation. BMJ Qual Saf. 2011;20(3):228-36. https://doi.org/10.1136/bmjqs.2010.043257
  13. 13Schünemann HJ, Wiercioch W, Brozek J, Etxeandia-Ikobaltzeta I, Mustafa RA, Manja V, et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol. 2017;81:101-10. https://doi.org/10.1016/j.jclinepi.2016.09.009
  14. 14Garritty C, Gartlehner G, Nussbaumer-Streit B, King VJ, Hamel C, Kamel C, et al. Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews. J Clin Epidemiol. 2021;130:13-22. https://doi.org/10.1016/j.jclinepi.2020.10.007
  15. 15Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-6. https://doi.org/10.1136/bmj.39489.470347.AD
  16. 16Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Dissolve-E FHIR implementation guide for the AWMF guideline registry: CodeSystem level of consensus [Internet]. [cited 2026 Nov 22]. Available from: https://fhir.awmf.org/awmf.ig/CodeSystem-cs-level-of-consensus.html
  17. 17Akl EA, Meerpohl JJ, Elliott J, Kahale LA, Schünemann HJ; Living Systematic Review Network. Living systematic reviews: 4. Living guideline recommendations. J Clin Epidemiol. 2017;91:47-53. https://doi.org/10.1016/j.jclinepi.2017.08.009
  18. 18Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Ausfüllhilfe zur Anmeldung eines Leitlinienvorhabens [Internet]. [cited 2026 Nov 22]. Available from: https://register.awmf.org/assets/documents/06_Ausfuellhilfe_Anmeldung.pdf

AWMFAWMF S3 guidelineAWMF RegelwerkRegelwerk 2.2S2e guidelineIQWiG evidence report

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation, so check its guide if it has one.

Dr. Charlie. (2026, November 22). AWMF S3 Guidelines: What the Rules Require from Systematic, Rapid and Scoping Reviews. Pubrica. https://pubrica.com/insights/regulatory-updates/awmf-s3-guidelines-evidence-reviews/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Next steps

Evidence reviews for German guideline groups

Pubrica’s systematic review team supports guideline groups with PICO key questions, documented searches, screening, risk of bias assessment, GRADE evidence profiles and rapid reviews that list every shortcut, in a format ready for the Leitlinienreport. We work to the group’s methods plan and the current AWMF Regelwerk but are not affiliated with or accredited by the AWMF. The guideline group keeps ownership of and responsibility for the recommendations, and timelines are agreed project by project.

This article is general information for researchers, not legal, regulatory or funding advice. Check the current requirements of your journal, funder, ethics committee or regulator before you act on it.

More in Regulatory Updates

All of Insights

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.